{"id":"NCT01160770","sponsor":"Lundbeck LLC","briefTitle":"Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome","officialTitle":"Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2012-02","completion":"2012-02","firstPosted":"2010-07-12","resultsPosted":"2013-05-06","lastUpdate":"2018-03-21"},"enrollment":267,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lennox-Gastaut Syndrome"],"interventions":[{"type":"DRUG","name":"Clobazam","otherNames":["Aedon, Antacastill, Castilium, Clarmyl, Frisium, Karidium, Mefrilan, Mystan, Noiafren, Onfi, Psiton, Psyton, Sentil, Seryl, Urbadan, Urbanil, Urbanol, Urbanyl."]}],"arms":[{"label":"Clobazam","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the long-term safety and effectiveness of open-label clobazam in the treatment of drop seizures in subjects with LGS.","primaryOutcome":{"measure":"Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment","timeFrame":"Baseline to month 36","effectByArm":[{"arm":"Clobazam","deltaMin":92.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23141144","27683846"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":115,"n":267},"commonTop":["Upper Respiratory Tract Infection","Pyrexia","Somnolence","Fall","Otitis Media"]}}